An In-Vitro Assessment of Anti-Tumor Activity of Some Plant Extract and Natural Products, Using Potato Discs Bioassay Technique

   Objectives: This study aimed to examine some plant extracts and natural products for anti-tumor activity. Methodology: Potato disc bioassay was used to estimate anti-tumor activity of some plant extracts and natural products. Five plant extracts and natural products recommended in a questionnaire filled by local botanists in addition to an introduced fermented food “Manda Koso” were used in this study. Study design: A questionnaire was designed and filled by 60 botanists looking for plant extracts and natural products having anti-cancer activity. In addition, computer surveys were conducted for gathering information on promising natural compounds act as anticancer agents. The potato disc bioassay was conducted using the Complete Randomized Design with three replicates. Each treatment in each replicate was represented by two Petri dishes contained five potato discs each. Petri dishes treated with sterilized water were used as control. Four separate experiments were carried out using TLC technique. Results & Discussion: Results showed highly significant differences among treatments with respect to total number of tumors and inhibition average percentage (%). The inhibition average percentage (IAP) for the different products ranged between 80.95-100% for the different products and equal zero for the control. It was 100% for Manda Kosa and bees honey followed by 90.23% for olive oil. Other treatments showed moderate anti-tumor effect of 80.95% IAP. Conclusions: Results concluded that Manda Koso, bees honey and olive oil have anti-tumor activity. Great association was found between anti-tumor activity obtained in this study and those published for anticancer activity of the promising material. الملخص: أجريت الدراسة بمعمل الاحياء الدقيقة بكلية الهندسة والتكنولوجيا بجامعة الجزيرة فى الفترة من 3 ابريل وحتى21 سبتمبر(2008) وذلك بغرض دراسة  مقدرة بعض المستخلصات النباتية على تثبيط  الاورام المستحثة باستخدام   سلالة محلية من  البكتيريا الزراعية  Agrobacterium tumefaceins تسمى SDB0012”" وذلك باستخدام تقنية قرص البطاطس وتقنية الفصل الكروماتوجرافى للتعرف على الجزيئات الفعالة للمستخلصات الطبيعية المستخدمة فى هذه الدراسة. اوضحت النتائج فروقات معنوية عالية ما بين المستخلصات المستخدمة في العدد الكلي للاورام  واحجامها.   اعطي  المستخلص اليابانى ماندا كوسو " Manda Koso" فعالية عالية على التثبيط الكلي للأورام المستحثة,  تليها عينة محلية لعسل النحل ثم زيت الزيتون ثم زيت الحبة السوداء (الكمون) ثم زيت الثوم  واقل نسبة رصدت في زيت الحلبة. أوصت الدراسة لاستخدام كل من ماندا كوسو, العسل و زيت الحبة السوداء كمثبطات نمو الاورام. اتضح من خلال هذه الدراسة فعالية استخدام تقنية اقراص البطاطس في تحديد مثبطات لنمو الاورام في كل من البطاطس والانسان وذلك من خلال تقارب النتائج بين هذا الاختبار في هذه التجربة و النتائج العالمية في هذه المستخلصات. هذا وقد اقترحت الدراسة إجراء استخدام تقنيات الفصل الكروماتوجرافى و كروماتوجرافيا الغاز GC و تقنية HPLC  بالاضافة لتقنية الهجرة الكهربية electrophoresis gel لفصل البروتينات

Resistance of Melons (Cucumis melo L.) to leafminers (Liriomyza spp.; Diptera: Agromyzidae

The vegetable leafminers, Liriomyza spp. (Diptera: Agromyzidae( are considered as one of the most important pests affecting vegetable crop production in many parts of the world. The reason why Liriomyza spp. are serious problems is the enormous build up of populations which are able to feed on a wide range of plant species. In the Sudan, two species of Liriomyza were reported: L. trifolii Burgess and L. sativae Blanchard' causing severe damage to a wide range of hosts. Recent surveys in central Sudan confirmed the existence of both species and that Liriomyza sativae was more common than L. trifolii on different host plants (Salah, 2001). The host range of L. sativae is confined to three families: Cucurbitaceae, Leguminaceae and Solanaceae, while L. trifolii is a polyphagous species, which attacks tomato, cucumber, lettuce, pepper and is also a serious problem on melons (Dogimont et al., 1999)

Identification of a Natural Source of Resistance to Watermelon Chlorotic Stunt Virus in an Indigenous Accession of Cucumis Melo Var. Agrestis

Watermelon chlorotic stunt virus (WCSV) is among the most important viral diseases of the family Cucurbitaceae. It is a bipartite begomovirus (DNA-A and DNA-B genome components) that belongs to the family Geminividae (Walkely et al., 1990). It causes severe crop losses, particularly in watermelon and melon (Lecoq et al.,1994). In Sudan, WCSV causes high reduction in yield and quality of watermelon, melon, snake cucumber and squashes. Leaves of infected plants are crinkled, stunted and develop striking chlorotic mottle. The whole plant looked stunted and chlorotic and may be devoid of marketable fruits (Walkely et al., 1990). Resistance to major diseases is very common among indigenous Sudanese melons, Tibish and agrestis (C. melo var. agrestis), compared to other melon types (Mohamed, 2000).    Experiments were conducted at the University of Gezira Research Farm in April (1996-1997) to identify a natural source of resistance to watermelon chlorotic stunt virus in Cucumis melo L. The screened material included: 101 accessions of C. melo var. cantalupensis and C. melo var flexuousus collected in Sudan; nine accessions belong to the indigenous Humaid type (C. melo var. agrestis) and eleven introduced lines such as P1 313970, P1 131375, Pl 255478, Vedrantais, Nantais Oblong, MR-I, Isoblon, Virgos, Margot and Zumo. The inoculation pressure of the virus in the field was increased by growing plants of the susceptible watermelon cultivar "Sugar Baby", obtained from Peto Seed Company, about one month before conducting the screening experiments

Genetics and Stability of Resistance to Watermelon Chlorotic Stunt Virus in Melon (Cucumis Melo L).

Experiments were carried out under field conditions at the University Gezira Research Farm, Sudan and the agroinoculation and green houses conditions in France (le Centre National de la Recherche Scientifique (CNRS*) and le Institut National de la Recherche Agronomique (INRA**) to study the inheritance and stability of resistance to watermelon chlorotic stunt virus (WCSV) in melon (C. melo L.).   The techniques of autoradiography, using the ratioactive WCSV P32, probe was used to detect WCSV in plant tissue and the phospho-imager machine was used to obtain quantified results of DNA particles within the examined plant tissue. The results indicated the presence of one dominant gene and another recessive independent gene controlling WCSV resistance in the resistant lines P1414723, P1124112 and HSD2445- 005. Multi-locational trials on resistant lines under natural field conditions revealed that the resistance to WCSV in melon is uniform and stable. Results of studying the movement of the virus within the plant tissues indicated that the blockage in the plant indigenous trafficking system was one of the mechanisms that are involved in plant resistance to WCSV in the lines P1414723, P1282448, P1124440, Pl 124112, 90625 and HSD 2445-005

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council

The development and validation of a scoring tool to predict the operative duration of elective laparoscopic cholecystectomy

Background: The ability to accurately predict operative duration has the potential to optimise theatre efficiency and utilisation, thus reducing costs and increasing staff and patient satisfaction. With laparoscopic cholecystectomy being one of the most commonly performed procedures worldwide, a tool to predict operative duration could be extremely beneficial to healthcare organisations. Methods: Data collected from the CholeS study on patients undergoing cholecystectomy in UK and Irish hospitals between 04/2014 and 05/2014 were used to study operative duration. A multivariable binary logistic regression model was produced in order to identify significant independent predictors of long (> 90 min) operations. The resulting model was converted to a risk score, which was subsequently validated on second cohort of patients using ROC curves. Results: After exclusions, data were available for 7227 patients in the derivation (CholeS) cohort. The median operative duration was 60 min (interquartile range 45–85), with 17.7% of operations lasting longer than 90 min. Ten factors were found to be significant independent predictors of operative durations > 90 min, including ASA, age, previous surgical admissions, BMI, gallbladder wall thickness and CBD diameter. A risk score was then produced from these factors, and applied to a cohort of 2405 patients from a tertiary centre for external validation. This returned an area under the ROC curve of 0.708 (SE = 0.013, p  90 min increasing more than eightfold from 5.1 to 41.8% in the extremes of the score. Conclusion: The scoring tool produced in this study was found to be significantly predictive of long operative durations on validation in an external cohort. As such, the tool may have the potential to enable organisations to better organise theatre lists and deliver greater efficiencies in care

Sex difference and intra-operative tidal volume: Insights from the LAS VEGAS study

BACKGROUND: One key element of lung-protective ventilation is the use of a low tidal volume (VT). A sex difference in use of low tidal volume ventilation (LTVV) has been described in critically ill ICU patients.OBJECTIVES: The aim of this study was to determine whether a sex difference in use of LTVV also exists in operating room patients, and if present what factors drive this difference.DESIGN, PATIENTS AND SETTING: This is a posthoc analysis of LAS VEGAS, a 1-week worldwide observational study in adults requiring intra-operative ventilation during general anaesthesia for surgery in 146 hospitals in 29 countries.MAIN OUTCOME MEASURES: Women and men were compared with respect to use of LTVV, defined as VT of 8 ml kg-1 or less predicted bodyweight (PBW). A VT was deemed 'default' if the set VT was a round number. A mediation analysis assessed which factors may explain the sex difference in use of LTVV during intra-operative ventilation.RESULTS: This analysis includes 9864 patients, of whom 5425 (55%) were women. A default VT was often set, both in women and men; mode VT was 500 ml. Median [IQR] VT was higher in women than in men (8.6 [7.7 to 9.6] vs. 7.6 [6.8 to 8.4] ml kg-1 PBW, P < 0.001). Compared with men, women were twice as likely not to receive LTVV [68.8 vs. 36.0%; relative risk ratio 2.1 (95% CI 1.9 to 2.1), P < 0.001]. In the mediation analysis, patients' height and actual body weight (ABW) explained 81 and 18% of the sex difference in use of LTVV, respectively; it was not explained by the use of a default VT.CONCLUSION: In this worldwide cohort of patients receiving intra-operative ventilation during general anaesthesia for surgery, women received a higher VT than men during intra-operative ventilation. The risk for a female not to receive LTVV during surgery was double that of males. Height and ABW were the two mediators of the sex difference in use of LTVV.TRIAL REGISTRATION: The study was registered at Clinicaltrials.gov, NCT01601223

The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

INTRODUCTION Investment in Africa over the past year with regard to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing has led to a massive increase in the number of sequences, which, to date, exceeds 100,000 sequences generated to track the pandemic on the continent. These sequences have profoundly affected how public health officials in Africa have navigated the COVID-19 pandemic. RATIONALE We demonstrate how the first 100,000 SARS-CoV-2 sequences from Africa have helped monitor the epidemic on the continent, how genomic surveillance expanded over the course of the pandemic, and how we adapted our sequencing methods to deal with an evolving virus. Finally, we also examine how viral lineages have spread across the continent in a phylogeographic framework to gain insights into the underlying temporal and spatial transmission dynamics for several variants of concern (VOCs). RESULTS Our results indicate that the number of countries in Africa that can sequence the virus within their own borders is growing and that this is coupled with a shorter turnaround time from the time of sampling to sequence submission. Ongoing evolution necessitated the continual updating of primer sets, and, as a result, eight primer sets were designed in tandem with viral evolution and used to ensure effective sequencing of the virus. The pandemic unfolded through multiple waves of infection that were each driven by distinct genetic lineages, with B.1-like ancestral strains associated with the first pandemic wave of infections in 2020. Successive waves on the continent were fueled by different VOCs, with Alpha and Beta cocirculating in distinct spatial patterns during the second wave and Delta and Omicron affecting the whole continent during the third and fourth waves, respectively. Phylogeographic reconstruction points toward distinct differences in viral importation and exportation patterns associated with the Alpha, Beta, Delta, and Omicron variants and subvariants, when considering both Africa versus the rest of the world and viral dissemination within the continent. Our epidemiological and phylogenetic inferences therefore underscore the heterogeneous nature of the pandemic on the continent and highlight key insights and challenges, for instance, recognizing the limitations of low testing proportions. We also highlight the early warning capacity that genomic surveillance in Africa has had for the rest of the world with the detection of new lineages and variants, the most recent being the characterization of various Omicron subvariants. CONCLUSION Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve. This is important not only to help combat SARS-CoV-2 on the continent but also because it can be used as a platform to help address the many emerging and reemerging infectious disease threats in Africa. In particular, capacity building for local sequencing within countries or within the continent should be prioritized because this is generally associated with shorter turnaround times, providing the most benefit to local public health authorities tasked with pandemic response and mitigation and allowing for the fastest reaction to localized outbreaks. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century

Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.

BACKGROUND: Remote ischaemic conditioning with transient ischaemia and reperfusion applied to the arm has been shown to reduce myocardial infarct size in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). We investigated whether remote ischaemic conditioning could reduce the incidence of cardiac death and hospitalisation for heart failure at 12 months. METHODS: We did an international investigator-initiated, prospective, single-blind, randomised controlled trial (CONDI-2/ERIC-PPCI) at 33 centres across the UK, Denmark, Spain, and Serbia. Patients (age >18 years) with suspected STEMI and who were eligible for PPCI were randomly allocated (1:1, stratified by centre with a permuted block method) to receive standard treatment (including a sham simulated remote ischaemic conditioning intervention at UK sites only) or remote ischaemic conditioning treatment (intermittent ischaemia and reperfusion applied to the arm through four cycles of 5-min inflation and 5-min deflation of an automated cuff device) before PPCI. Investigators responsible for data collection and outcome assessment were masked to treatment allocation. The primary combined endpoint was cardiac death or hospitalisation for heart failure at 12 months in the intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02342522) and is completed. FINDINGS: Between Nov 6, 2013, and March 31, 2018, 5401 patients were randomly allocated to either the control group (n=2701) or the remote ischaemic conditioning group (n=2700). After exclusion of patients upon hospital arrival or loss to follow-up, 2569 patients in the control group and 2546 in the intervention group were included in the intention-to-treat analysis. At 12 months post-PPCI, the Kaplan-Meier-estimated frequencies of cardiac death or hospitalisation for heart failure (the primary endpoint) were 220 (8·6%) patients in the control group and 239 (9·4%) in the remote ischaemic conditioning group (hazard ratio 1·10 [95% CI 0·91-1·32], p=0·32 for intervention versus control). No important unexpected adverse events or side effects of remote ischaemic conditioning were observed. INTERPRETATION: Remote ischaemic conditioning does not improve clinical outcomes (cardiac death or hospitalisation for heart failure) at 12 months in patients with STEMI undergoing PPCI. FUNDING: British Heart Foundation, University College London Hospitals/University College London Biomedical Research Centre, Danish Innovation Foundation, Novo Nordisk Foundation, TrygFonden